Pharma Ceos Tackle a Tough Question: for Good Real Estate on Formularies
Total Page:16
File Type:pdf, Size:1020Kb
Winter Is Coming: What Can Novo BMS’ Mike Burgess Talks Challenges Stockwatch Nordisk Do Next After Stock Fall? and Developments In 2017 Drug failures in Phase III and value- Recent stock tumble and struggles What should we expect from BMS based pricing were two forces affecting have revealed armored Novo’s soft outside of oncology in 2017? (p16) Horizon and Vertex last week (p21) underbelly (p4) 16 December 2016 No. 3833 Scripscrip.pharmamedtechbi.com Pharma intelligence | informa year. That’s a very efficient way of increasing profits without innovation.” No one else was quick to agree with that suggestion, however. Pfizer’s Read re- sponded, “I totally disagree with that.” He said the cost of drugs system-wide has not changed in two decades. “Whether you talk about three prices a year, two prices a year, double-digits, the cost of drugs has not changed,” he insisted. Lilly’s Ricks pointed to his company’s experience with insulin, which has come under attack from the public because of increasing cost. “Our net pricing hasn’t changed in seven years. It’s gone down slightly,” he said. “Our net is flat to declining.” But, he added, “The patient hasn’t seen any of that.” The reason is because pharma com- Shutterstock: Jirsak Shutterstock: panies often increase the wholesale list cost of drugs, then return money to payers in the form of rebates and discounts in exchange Pharma CEOs Tackle A Tough Question: for good real estate on formularies. Milligan, who as a top executive at Gilead has experienced his share of public criticism ‘Why Don’t People Like You?’ over the $1,000-per-pill price of the hepatitis JESSICA MERRILL [email protected] C treatment Sovaldi, talked about the need to work with payers and how that relation- Pfizer CEO Ian Read, Regeneron CEO & Co. incoming CEO David Ricks and Astellas ship contributes to the overall problem. Leonard Schleifer, Gilead CEO John Milli- Pharma Inc. president-Astellas Americas Jim One of the biggest issues with the price of gan and Lilly’s incoming CEO David Ricks Robinson were asked by Forbes editor Mat- Sovaldi was the substantial bolus of patients discussed pharma’s reputation problem thew Herper to answer a tough question at waiting to receive treatment, which pushed during the Forbes Healthcare Summit. the Forbes Healthcare Summit in New York a lot of people into the system at the same Dec. 1: “Why don’t people like you?” time, posing a unique challenge to insurers. panel of A-list pharmaceutical in- Regeneron’s Schleifer was the one that “We were unable to have a good enough dustry CEOs tried to boil down why answered the question the most directly. conversation with the payers” about Gil- Ait is that an industry that develops “The real reason we aren’t liked, in my view, ead’s HCV drugs, Milligan said. “Perhaps we life-improving medicines has a bad reputa- is because we, as an industry, have used were a little conservative about what we tion in the eyes of the public – though they price increases to cover up the gaps in in- could or should have said to them to al- never really did agree on the answer. novation,” he said. low them to prepare for the number of pa- Pfizer Inc. CEO Ian Read, Regeneron Phar- “I may be kicked off the all-star team,” tients that came forward.” As part of recent maceuticals Inc. CEO Leonard Schleifer, Gil- Schleifer joked, “But it’s just a fact. The price discussions on off-label communication, ead Sciences Inc. CEO John Milligan, Eli Lilly of drugs has gone up double digits twice a CONTINUED ON PAGE 7 BROUGHT TO YOU BY THE EDITORS OF PHARMASIA NEWS, START-UP AND SCRIP INTELLIGENCE IN THIS ISSUE Drug treatment for hearing loss Gap between invoice, prices widening 5 Pfizer fined in UK 8 20 COVER / Pharma CEOs Tackle A Tough Question: from the editor ‘Why Don’t People Like You?’ [email protected] 3 Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal Even pharma CEOs can’t agree on the question of 4 Winter Is Coming: What Can Novo Nordisk Do Next drug pricing: Pfizer’s Ian Read and Eli Lilly’s David After Stock Fall? Ricks squared off against Regeneron’s Leonard Schei- fler on this topic at the Forbes Healthcare summit, 5 Decibel Therapeutics: Protect. Repair. Restore. where this season’s pharma villain Heather Bresch 6 New Global Generics Head At Teva also took the stage in defense of Mylan’s EpiPen price 6 Bullish Lilly Takes On New Alzheimer’s Candidate increases. In the UK, Pfizer and Flynn were fined for exploiting a loophole to hike the price of an off-pat- 7 Novartis’ Zykadia ASCEND-4 Study Close But ent epilepsy drug by up to 2,600%. No Cigar In NSCLC Most pharma companies declare they aim to serve 8 UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ patients. Actions speak louder than words, though, Pricing Sends Clear Message To Others and the actions of those who adopt price inflation as 10 After Solanezumab, What’s Next? Alzheimer’s Options a business model simultaneously create pain for pa- Take The Stage At CTAD tients and tarnish the image of the industry. This is particularly galling for companies that eschew such 13 R&D Bites practices. It is also ironic that the generics sector, 12 Lilly’s Alzheimer’s EXPEDITION3 Proves Positive which should drive down prices on patent-expired For Biogen’s Anti-Amyloid At CTAD drugs, is responsible for some of the most controver- 14 Jardiance’s Label Expansion Will Change Diabetes sial price increases. Some of the blame can be shared Management with PBMs, insurers and the supply chain, but the fact remains that certain firms have exploited pricing 14 AbbVie/J&J’s Imbruvica On Track For GvHD confusion to practise pricing abuse, and ultimately 15 Sanofi Turns To Digital Transformation In Crisis-Hit that’s not good for patients or for pharma. China Vaccines Market 16 Interview: Bristol-Myers’ Mike Burgess Talks R&D Challenges, Portfolio Developments In 2017 17 Xencor To Raise $110m For IO Pipeline exclusive online content 18 Business Bulletin VIDEO: Dimerix CEO Explains Company’s Different 19 Mylan Plans Workforce Reduction After M&A And Drug Combo R&D Strategy Price Scandal Global director of content for Informa Pharma Intelligence, Mike 20 Policy & Regulation Briefs Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company’s unusual business model. 21 Stockwatch: What Links Actimmune And Vertex’s http://bit.ly/2hljnlb Event Horizon? AiCuris Seeks Partners For Antibacterial Programs 22 Pipeline Watch AiCuris CEO Holger Zimmermann talks to Mike Ward, global 23 Appointments director of content for Informa Pharma Intelligence, about the company’s journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. http://bit.ly/2gDx6oU @scripnews /scripintelligence /scripintelligence /scripintelligence 2 | Scrip intelligence | 16 December 2016 © Informa UK Ltd 2016 HEADLINE NEWS Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal CEO Heather Bresch defended her company’s controversial decision to raise the price of the allergy medicine to $600 during the Forbes Healthcare Summit and even took questions from fellow pharma insiders like “Why did you ruin it?” JESSICA MERRILL [email protected] ylan NV CEO Heather Bresch, who The Forbes audience was notably a pricing scandals, like Mylan with EpiPen or became a central figure in the friendlier one than Bresch has confronted Turing Pharmaceuticals AG’s extravagant Mpublic drama that played out ear- in Washington, D.C., and some other ven- price hikes for Daraprim (pyrimethamine), lier this year over the EpiPen (epinephrine) ues, but participants still put pressure on which resulted in former CEO Martin Shkre- drug pricing scandal, continues to defend her to justify the company’s actions. One li being hit with fraud charges. the company’s decision to substantially raise audience member, pointing to some of the Most pharma executives have tried to the price of the life-saving allergy medicine good work Mylan has done providing af- paint those incidences as one-off examples and put some of the responsibility at other fordable HIV medicines to patients in Africa, of bad actors putting a negative spotlight players in the distribution chain. asked, “Why did you ruin it? What you did on the broader industry, though double- “We got a lot of things right [with was take all that good will and destroy it.” digit price increases on mature medicines EpiPen], but we got some things wrong,” Bresch responded, “We have spent $1bn annually or even more frequently are large- Bresch acknowledged to a room full of over the last eight years. That investment ly a standard practice across the industry. pharma insiders during the Forbes Health- was real and we believe it has produced Bresch insisted Mylan is not a bad actor. care Summit in New York City Dec. 1. What significant results.” “That is not who we are. We have a real op- the company failed to recognize as it raised portunity to show who Mylan is,” she said. the price of EpiPen from $100 in 2008 to ‘I do believe the system “We are not the company that bought a $600 in 2016 was how health insurance product, raised the price overnight and had changed and how that change would needs to be reinvented,’ our business model is not just taking old impact the ability of consumers to pay for Bresch said products and raising prices.” She pointed the medicine, she said.